Company Overview and News

2
Broker's Call

2018-10-08 thehindubusinessline
Ajanta Pharma is a holding company. The company is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations.
WIT 532331 AJANTPHARM

 
Ajanta Pharma Limited - Allotment of ESOP/ESPS

2018-09-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

 
D-Street Buzz: Nifty pharma outperforms with Sun Pharma up 2%; RIL advances, Advanced Enzyme jumps 9%

2018-09-05 moneycontrol
The Indian benchmark indices are trading on a flat to positive note this Wednesday morning with the Nifty50 trading at 11,521, up 1 point while the Sensex is trading higher by 38 points at 38,196.
ESL SUZLON MUTHOOTFIN 500325 AUROPHARMA RELIANCE 533398 TATACOMM 532733 CADILAHC CSLQY 532321 532221 SONATSOFTW RIGD AJANTPHARM 520086 GAILF BEL SUEL SUNTV RLNIY 500870 BHQRY 524804 533264 532667 CDLYY CASTROLIND 532331 ARBQY GAILY SICAL SNQVY 500049 500483

 
Ajanta Pharma Limited - Resignation

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

 
Ajanta Pharma Limited - Investor Presentation

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

 
Ajanta Pharma Limited - Outcome of Board Meeting

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

 
Ajanta Pharma Limited - Financial Result Updates

2018-07-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

4
Vedanta, Tata Motors, BoI, BEL, Dabur results

2018-07-30 thehindubusinessline
Over 70 companies will declare their April-June results on Tuesday. Among these are Ajanta Pharma, Bank of India, BASF India, BEL, Blue Dart Express, Cigniti Tech, Dabur India, EIH, Eimco, FACT, Federal Mogul, Future Market, GSFC, Huhtamaki, IIFL Holdings, JK Paper, LG Balakrishnan, Mahanagar Gas, Mangalore Chem, Morepen Labs, PowerGrid, Raymond, Snowman Logistics, Subex, Supreme Ind, Tata Motors, Uniphos Enterprises, UPL, Vedanta and V-Guard Industries.
500429 DABUR IIFL BASF 532636 DBRQY 532953 538635 532331 500096 UNIPHOS 532162 VGUARD AJANTPHARM 500570 500042 SNOWMAN TATAMOTORS 526612 BLUEDART JKPAPER TTM

 
USFDA inspects Dahej facility, no observations issued: Ajanta Pharma

2018-07-27 moneycontrol
Drug firm Ajanta Pharma today said the US health regulator has not made any observations after completion of inspection of its Dahej facility in Gujarat. "Our formulation facility at Dahej was inspected by US FDA from July 23-27, 2018. At the end of the inspection, no Form 483 was issued to us," Ajanta Pharma said in a BSE filing.
532331 AJANTPHARM

 
Ajanta Pharma Limited - Updates

2018-07-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

 
Ajanta Pharma Limited - Trading Window

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

 
Ajanta Pharma under scanner for marketing unapproved drugs

2018-07-16 livemint
Mumbai: Ajanta Pharma Ltd has come under the regulator’s scanner for allegedly selling unapproved fixed-dose combinations (FDCs) manufactured by a Puducherry firm.
532331 AJANTPHARM

 
Ajanta Pharma Limited - News Clarification

2018-07-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532331 AJANTPHARM

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...